Clinical Trial: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07709715) titled 'A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis' on July 12.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

Study Start Date: Jan., 2027

Study Type: INTERVENTIONAL

Condition: Light Chain (AL) Amyloidosis

Intervention: BIOLOGICAL: NXC-201

NXC-201 CAR-T is defined a...